Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 3/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669439 | 0.98 | HDAC4 (0.49) | HDAC4AKR1C1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL6670890 | 0.93 | HDAC4 (0.42) | HDAC4AKR1C1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14899045 | 0.77 | AKR1C1 (0.48) | HDAC4AKR1C1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL27584803 | 0.77 | HDAC4 (0.44) | HDAC4AKR1C1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14216801 | 0.77 | TSHR (0.42) | HDAC4 | |
| SCHEMBL1953126 | 0.75 | AKR1C1 (0.50) | HDAC4AKR1C1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL290754 | 0.74 | HDAC4 (0.50) | HDAC4AKR1C1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL27774530 | 0.74 | HDAC4 (0.50) | HDAC4AKR1C1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL27742158 | 0.74 | AKR1C1 (0.48) | HDAC4AKR1C1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL28776197 | 0.72 | SLC6A4 (0.50) | HDAC4AKR1C1SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | HDAC4 648/4885AKR1C1 485/4885SLC6A4 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.